S&P 500 7,498.96 -0.14% NASDAQ 25,690.90 -0.57% DOW 52,218.58 -0.01% R2K 2,959.94 -0.92% VIX 16.64 -2.40% US 10Y 4.66 +0.63% DXY 101.14 -0.04% GOLD 4,124.10 +1.30% CRUDE 87.92 +3.54% BITCOIN 65,998.96 -0.76%

S&P 500 7,498.96 -0.14% NASDAQ 25,690.90 -0.57% DOW 52,218.58 -0.01% R2K 2,959.94 -0.92% VIX 16.64 -2.40% US 10Y 4.66 +0.63% DXY 101.14 -0.04% GOLD 4,124.10 +1.30% CRUDE 87.92 +3.54% BITCOIN 65,998.96 -0.76%

Next Bullish Trade

Sign in

Account

Create free accountFree dashboard, no payment Sign inEmail yourself a login link CoursesYour library & catalog

SUPN

Supernus Pharmaceuticals, Inc. NGM · SUPN

$46.94 -0.93 (-1.94%)

Neutral · -0.22σ Grade C

+ Compare Open in Sniper

News · SUPN

Full news feed →

Supernus Pharmaceuticals to Participate in the Bank of America 2026 Health Care Conference

GlobeNewswire Inc. · 77d ago

Supernus Pharmaceuticals to Participate in March Investor Conferences

GlobeNewswire Inc. · 149d ago

Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back

The Motley Fool · 218d ago

Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer

Benzinga · 359d ago

Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire Inc. · 526d ago

Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference

GlobeNewswire Inc. · 603d ago

Attention-Deficit Hyperactivity Disorder Treatment Market is projected to Reach USD 15.4 Billion, Garnering A 3.1% CAGR from 2024 to 2034 | Report Analysis by Transparency Market Research Inc.

GlobeNewswire Inc. · 709d ago

Supernus Pharmaceuticals to Announce Second Quarter 2024 - GlobeNewswire

GlobeNewswire Inc. · 729d ago

Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?

Zacks Investment Research · 789d ago

Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy

GlobeNewswire Inc. · 790d ago

Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures

GlobeNewswire Inc. · 804d ago

Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics

Zacks Investment Research · 805d ago

Supernus Announces First Quarter 2024 Financial Results

GlobeNewswire Inc. · 805d ago

Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story

GlobeNewswire Inc. · 812d ago

Supernus Provides Regulatory Update for SPN-830

GlobeNewswire Inc. · 835d ago

Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference

GlobeNewswire Inc. · 875d ago

Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks Investment Research · 875d ago

Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates

Zacks Investment Research · 876d ago

BridgeBio Pharma (BBIO) Reports Q4 Loss, Lags Revenue Estimates

Zacks Investment Research · 881d ago

Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for

Zacks Investment Research · 883d ago

Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent

GlobeNewswire Inc. · 898d ago

Supernus Pharmaceuticals (SUPN) Reports Q3 Loss, Tops Revenue Estimates

Zacks Investment Research · 986d ago